Breaking News Instant updates and real-time market news.

EA

Electronic Arts

$100.96

0.19 (0.19%)

, ATVI

Activision Blizzard

$54.83

0.35 (0.64%)

07:16
12/02/19
12/02
07:16
12/02/19
07:16

Black Friday checks find strong demand for EA, Activision games, says Stephens

Stephens analyst Jeff Cohen said his retail checks around Black Friday pointed to strong demand for Electronic Arts' (EA) sports games as well as "Jedi Fallen Order," along with Activision's (ATVI) "Call of Duty Modern Warfare." Given strong word of mouth, reviews, and excitement around the Star Wars franchise, Cohen said he expects "Jedi Fallen Order" to continue selling well through the holiday season, adding that he believes EA shares will break out of the $90-$100 range they have been in for most of 2019. Cohen has Overweight ratings on both EA and Activision, which he calls his top picks in the console gaming space.

EA

Electronic Arts

$100.96

0.19 (0.19%)

ATVI

Activision Blizzard

$54.83

0.35 (0.64%)

  • 02

    Dec

  • 09

    Dec

  • 13

    Dec

EA Electronic Arts
$100.96

0.19 (0.19%)

10/30/19
BARD
10/30/19
NO CHANGE
Target $108
BARD
Outperform
Electronic Arts results overshadowed by pipeline concerns, says Baird
Baird analyst Colin Sebastian said Electronic Arts delivered solid Q results but he feels its report was overshadowed by out-year pipeline concerns. He said the pipeline shift raises questions about 2021 growth as management confirmed the next installment of its key Battlefield franchise will not ship until 2022. He noted Live Services showed impressive growth but mobile remained a relative weak spot. Sebastian reiterated his Outperform rating and lowered his price target to $108 from $114 on Electronic Arts shares.
10/30/19
SPHN
10/30/19
NO CHANGE
Target $120
SPHN
Overweight
Stephens remains buyer on EA weakness ahead of new 'Star Wars' game
Stephens analyst Jeff Cohen maintained an Overweight rating and $120 price target on Electronic Arts after the company delivered a beat-and-raise Q2 "driven by live services and EA Sports." Cohen noted, however, that investors will be focused on the announcement that the game maker will not have its expected "Battlefield" release next year but rather in fiscal 2022. The analyst said he believes it is the right move for the franchise and will allow the next "Battlefield" to launch into a larger installed base of new consoles in FY22. While this does put "significantly" more emphasis on live services and changes the earnings algorithm for fiscal 2021, Cohen said he sees a number of potential areas for revenue upside including Volta monetization, "Apex" in China on Steam, and "Star Wars" story downloadable content, and thus he remains a buyer ahead of "what should be a strong" release of "Star Wars Jedi: Fallen Order" on November 15.
11/15/19
PIPR
11/15/19
NO CHANGE
Target $106
PIPR
Overweight
EA's new Star Wars game seeing 'strong early reception,' says Piper Jaffray
Electronic Arts launched Star Wars Jedi: Fallen Order today and early reviews of the single-player game are materially outpacing prior EA Star Wars games and last year's Battlefield, Piper Jaffray analyst Michael Olson tells investors in a research note. The average Metascore for the title is 87.5 based on almost 50 reviews versus last year's Battlefield at 77.3 and Star Wars Battlefront II at 66.3, Olson points out. Based on the "strong early reception," the analyst believes his fiscal 2020 6M-8M unit estimate for Star Wars Jedi "is beginning to look conservative." He maintains an Overweight rating on Electronic Arts with a $106 price target.
11/26/19
RHCO
11/26/19
NO CHANGE
Target $107
RHCO
Buy
EA release implies 'Jedi Fallen Order' tracking at least in-line, says SunTrust
After Electronic Arts issued a press release this morning to announce that Star Wars Jedi Fallen Order is "the fastest-selling digital launch for a Star Wars game in its first two weeks," SunTrust analyst Matthew Thornton said he believes this means the game is tracking "at least in-line" with the midpoint of guidance for 6M-8M units for FY20. If the game is successful, as this morning's press releases seems to suggest, Thornton said he continue to expect EA to follow up the launch with paid downloadable content. Thornton keeps a Buy rating on EA shares with a $107 price target on the stock.
ATVI Activision Blizzard
$54.83

0.35 (0.64%)

11/08/19
COWN
11/08/19
NO CHANGE
Target $50
COWN
Outperform
Activision Blizzard results good but no clarity on new titles, says Cowen
Cowen analyst Doug Creutz said Activision Blizzard reported upside to its Q3 guidance on the top and bottom line but still provided no clarity on the timing of its new titles Overwatch 2 and Diablo 4, which may lead to investor nervousness around the company's guidance which was modestly raised for the year. Creutz reiterated his Outperform rating and raised his price target to $50 from $48 on Activision Blizzard shares.
11/08/19
NEED
11/08/19
NO CHANGE
Target $62
NEED
Buy
Activision Blizzard price target raised to $62 from $50 at Needham
Needham analyst Laura Martin raised her price target on Activision Blizzard to $62 and kept her Buy rating after its Q3 earnings beat. Despite the below-consensus outlook for Q4, the analyst maintains a positive view on its eSports category as Overwatch League billionaire owners of its teams have positive influence on business decisions and given the company's "significant hidden asset value" in moving its hit games to mobile devices.
11/08/19
SPHN
11/08/19
NO CHANGE
Target $65
SPHN
Overweight
'Strong' Q3 reinforces bull case for Activision Blizzard, says Stephens
Before the open, Stephens analyst Jeff Cohen backed an Overweight rating and $65 price target on Activision Blizzard after the company's "strong" third quarter earnings report. Cohen said that management's commentary was "positive" around the impact of "World of Warcraft Classic," the launch of "Call of Duty Mobile," and the launch of "Call of Duty: Modern Warfare." Due to the "impressive" signs of franchise re-invigoration at "Warcraft" and "Call of Duty" as well as the multiyear pipeline for Blizzard laid out at BlizzCon, the analyst said he expects long-term holders will be buyers on any weakness related to the "conservative" fourth quarter guidance.
11/27/19
JEFF
11/27/19
NO CHANGE
Target $65
JEFF
Buy
Activision's 'CoD Mobile' back among top 5 apps in U.S., says Jefferies
Jefferies analyst Alex Giaimo noted that Activision Blizzard's "Call of Duty Mobile" is back in the top 5 grossing apps in the U.S. following the launch of "Zombies" mode on November 24. "CoD Mobile" is currently a top 5 grossing app in 45 other countries as well, noted the analyst, who further said that reviews remain strong and he has early confidence in a consistent contribution from the game moving forward. Giaimo has a Buy rating and $65 price target on Activision Blizzard shares.

TODAY'S FREE FLY STORIES

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.